Clinical trials: Chronic Hepatitis D
Hepatitis B
Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
This Phase 1/2a multiple part study is a first time-in-human (FTIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single (Part 1) and repeat doses (Part 2) of GSK3965193 in healthy…
- Trial name
- NCT05330455
- Testing
- GSK3965193, Bepirovirsen
- Where
- 14 sites in Canada, France and 4 more
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis D Infection
Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).
- Trial name
- LOWR-1 (NCT02430181)
- Testing
- lonafarnib, peginterferon alfa-2a, ritonavir
- Where
- Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- EIT Pharma, Inc.
Chronic Hepatitis D Infection
Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)
An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib with Ritonavir Boosting +/- Peginterferon alfa-2a in Patients Chronically Infected with Delta Hepatitis (HDV) (LOWR-2).
- Trial name
- LOWR-2 (NCT02430194)
- Testing
- lonafarnib, ritonavir, Pegylated interferon-alfa-2a
- Where
- Turkey (Türkiye)
- Volunteers
- 55 people
- Sponsor
- EIT Pharma, Inc.
Chronic Delta Hepatitis
Titrating-Dose of Lonafarnib in Combination With Ritonavir
A phase 2, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of titrating-dose lonafarnib/ritonavir in patients chronically infected with hepatitis delta virus (HDV)
- Trial name
- LOWR-4 (NCT02527707)
- Testing
- lonafarnib, Ritonavir
- Volunteers
- 15 people
- Sponsor
- EIT Pharma, Inc.
Hepatitis D, Chronic
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
To evaluate safety and tolerability of lambda over a 48-week treatment period in HDV patients.
- Trial name
- LIMT (NCT02765802)
- Testing
- Peginterferon Lambda-1A
- Where
- 4 sites in Israel, New Zealand and 1 more
- Volunteers
- 33 people
- Sponsor
- EIT Pharma, Inc.
Chronic HCV Infection
Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis
A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non-severe fibrosis The primary…
- Trial name
- STREAGER (NCT02973503)
- Testing
- Elbasvir/Grazoprevir Fixed Dose Combination
- Where
- France
- Volunteers
- 117 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hepatitis B, Chronic
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection
- Trial name
- NCT04749368
- Testing
- BRII-835 (VIR-2218), BRII-179 (VBI-2601) with IFN-α, BRII-179 (VBI-2601)
- Where
- 28 sites in Australia, China and 4 more
- Volunteers
- 91 people
- Sponsor
- Brii Biosciences Limited
Hepatitis D, Chronic
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
The purpose of the study is to evaluate on-treatment efficacy against hepatitis D virus (HDV) of JNJ-73763989 + nucleos(t)ide analog (NA) regimen compared to NA alone.
- Trial name
- REEF-D (NCT04535544)
- Testing
- JNJ-73763989, Entecavir (ETV) monohydrate, Tenofovir disoproxil
- Where
- 61 sites in United States, Australia and 13 more
- Volunteers
- 52 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis C, Chronic, Substance Use Disorders
Linkage to Care for Persons With Hep C Infection
Hepatitis C Virus (HCV) infection is an ongoing challenge in the United States, with an estimated 2.4 million individuals living with HCV in 2016.
- Trial name
- NCT05397067
- Testing
- Peer specialist (PS), Incentives, telehealth visits
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Carilion Clinic
Chronic Hepatitis b
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.
- Trial name
- NCT04980482
- Testing
- AB-729, Peg-IFNα-2a
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 43 people
- Sponsor
- Arbutus Biopharma Corporation
Chronic Hepatitis B
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability…
- Trial name
- NCT04412863
- Testing
- VIR-2218, pegylated interferon-alfa 2a
- Where
- 22 sites in Australia, Hong Kong and 4 more
- Volunteers
- 84 people
- Sponsor
- Vir Biotechnology, Inc.
Hepatitis B, Chronic
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed participants under nucleo(s)tide treatment.
- Trial name
- NCT03866187
- Testing
- ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation
- Where
- 43 sites in Belgium, France and 7 more
- Volunteers
- 236 people
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
This is a Phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.
- Trial name
- NCT05612581
- Testing
- VIR-3434, VIR-2218, TDF
- Where
- 15 sites in France, Hong Kong and 4 more
- Volunteers
- 33 people
- Sponsor
- Vir Biotechnology, Inc.
Chronic Hepatitis B
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to < 12 years at the time of enrollment) with chronic…
- Trial name
- NCT01651403
- Testing
- Tenofovir DF
- Where
- 21 sites in United States, India and 3 more
- Volunteers
- 90 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B
The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.
- Trial name
- NCT05770895
- Testing
- GS-2829, GS-6779
- Where
- 9 sites in New Zealand, Taiwan
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tolerability and to characterize the pharmacokinetics and pharmacodynamics…
- Trial name
- NCT05763576
- Testing
- RO7565020, Nucleos(t)ide analogue (NUC) treatment
- Where
- 9 sites in United States, Hong Kong and 5 more
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to determine whether ARC-520 in combination with entecavir is effective in the treatment of patients with chronic HBV Infection.
- Trial name
- NCT02065336
- Testing
- ARC-520, entecavir, chlorpheniramine
- Where
- 2 sites in Hong Kong
- Volunteers
- 58 people
- Sponsor
- Arrowhead Pharmaceuticals
Chronic Hepatitis C
Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
This study is a 24-week multicenter, randomized, double-blind control trial with ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan.
- Trial name
- NCT00200343
- Testing
- Ursodeoxycholic acid 150mg / day, Ursodeoxycholic acid 600mg / day, Ursodeoxycholic acid 900mg / day
- Where
- Japan
- Volunteers
- 596 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Hepatitis C
Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.
- Trial name
- NCT00591214
- Testing
- MP-424 (Telaprevir)
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.
- Trial name
- NCT00621296
- Testing
- MP-424 (Telaprevir)
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Tanabe Pharma Corporation